CA2516364A1 - Methode de modulation - Google Patents

Methode de modulation Download PDF

Info

Publication number
CA2516364A1
CA2516364A1 CA002516364A CA2516364A CA2516364A1 CA 2516364 A1 CA2516364 A1 CA 2516364A1 CA 002516364 A CA002516364 A CA 002516364A CA 2516364 A CA2516364 A CA 2516364A CA 2516364 A1 CA2516364 A1 CA 2516364A1
Authority
CA
Canada
Prior art keywords
leu
inhibitory substance
ala
pro
mis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002516364A
Other languages
English (en)
Inventor
Ian Stuart Mclennan
Kyoko Koishi
Pei-Yu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otago Innovation Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2516364A1 publication Critical patent/CA2516364A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002516364A 2005-03-24 2005-09-16 Methode de modulation Abandoned CA2516364A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ539036 2005-03-24
NZ53903605 2005-03-24

Publications (1)

Publication Number Publication Date
CA2516364A1 true CA2516364A1 (fr) 2006-09-24

Family

ID=37035442

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002516364A Abandoned CA2516364A1 (fr) 2005-03-24 2005-09-16 Methode de modulation

Country Status (3)

Country Link
US (1) US20060216294A1 (fr)
AU (1) AU2005211556A1 (fr)
CA (1) CA2516364A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049977A2 (fr) * 2005-10-26 2007-05-03 Otago Innovation Limited Methode de modulation
CA2837472A1 (fr) * 2011-05-27 2012-12-06 Fox Chase Cancer Center Anticorps diriges contre le recepteur de type ii d'une substance inhibitrice anti-mullerienne concue de facon rationnelle
AU2014248768A1 (en) 2013-03-12 2015-09-24 Massachusetts Eye And Ear Infirmary Modified mullerian inhibiting substance (MIS) proteins and uses thereof for the treatment of diseases
WO2015041718A1 (fr) * 2013-09-20 2015-03-26 The General Hospital Corporation Utilisations de protéines de type hormone anti-müllérienne (ham) modifiée pour le traitement de maladies neurodégénératives
CA3151082A1 (fr) 2013-12-11 2015-06-18 The General Hospital Corporation Utilisation de proteines d'hormone anti-mullerienne (amh) pour la contraception et la preservation de la reserve ovarienne
WO2018112168A1 (fr) 2016-12-14 2018-06-21 The General Hospital Corporation Protéines d'hormone anti-müllérienne (ham) pour l'oncoprotection ovarienne et utérine, et réserve ovarienne et conservation utérine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5198420A (en) * 1989-10-02 1993-03-30 The General Hospital Corporation Use of mullerian inhibiting substance and its agonists and antagonists in the treatment of respiratory distress syndrome
WO1993019177A1 (fr) * 1992-03-18 1993-09-30 The General Hospital Corporation QUATRE NOUVEAUX RECEPTEURS APPARTENANT A LA FAMILLE DES RECEPTEURS TGF-$g(b)
US6673352B1 (en) * 1999-09-14 2004-01-06 The General Hospital Corporation Use of Mullerian inhibiting substance for treating excess androgen states
WO2001055212A2 (fr) * 2000-01-27 2001-08-02 The General Hospital Corporation Administration de produits biologiques therapeutiques a partir de matrices tissulaires implantables

Also Published As

Publication number Publication date
US20060216294A1 (en) 2006-09-28
AU2005211556A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
JP2012525847A (ja) Ｆｇｆ２１変異体およびその使用
CN101137668A (zh) 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法
CA2516364A1 (fr) Methode de modulation
KR20170031668A (ko) 면역 조절을 위한 방법 및 조성물
US20140213526A1 (en) Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
SK15262002A3 (sk) Peptid modulujúci trombopoetínový receptor
JP2004504011A (ja) 細胞外マトリクスポリヌクレオチド、ポリペプチドおよび抗体
JP2000509967A (ja) カルシウムチャンネルモジュレーターとして活性のあるアセチルコリンエステラーゼの可溶形態からのペプチド
JP2024026109A (ja) 疼痛を治療し、疼痛感受性を増大させるためのペプチド及び他の薬剤
US20090304675A1 (en) Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases
US20060286117A1 (en) Neuronally expressed stem cell factor modulates angiogenesis and neural stem cell migration to areas of brain injury
JP2005534641A (ja) Ｆａｓペプチド模倣体およびその使用
US20070173453A1 (en) Methods of preventing or treating brain ischemia or brain injury
JP2023516325A (ja) 血中コレステロール低下用、心血管代謝疾患の予防又は治療用及び抗炎症用薬学的組成物
EP3037817B1 (fr) Procédé de criblage des inhibiteurs de la douleur et composition pharmatheutique pour la prevention ou le traitement de la douleur
US20080249038A1 (en) Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof
KR20100080769A (ko) 과민성 반응의 조절자
JP2003523760A (ja) ヒトポリヌクレオチド、ポリペプチド、および抗体
US20090298756A1 (en) Functions and uses of gpr39 gene in mammalian central nervous system
CN112316118B (zh) Amhr2重组蛋白或融合蛋白在制备amh信号轴异常活化相关疾病治疗药物中的用途
JP2003525628A (ja) プロテインチロシンホスファターゼポリヌクレオチド、ポリペプチド、および抗体
JP2003527841A (ja) 三つ葉ドメイン含有ポリヌクレオチド、ポリペプチドおよび抗体
JP5447784B2 (ja) マキサディランの部分ペプチドを含む神経因性疼痛の治療剤
CA3225321A1 (fr) Ptprs dans l'auto-immunite
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂

Legal Events

Date Code Title Description
FZDE Discontinued